Ronn AM, Bygbjerg IC: The roles from the pfcrt 76 T and pfmdr1 86Y mutations, immunity plus the initial amount of parasitaemia, in predicting the outcome of chloroquine treatment in two places with unique transmission intensities. Ann Trop Med Parasitol 2005, 99:441?48. 40. MOH: Anti-Malaria Drug Policy for Ghana. Accra, Ghana: Ministry of Overall health; 2009. 41. Kwansa-Bentum B, Ayi I, Suzuki T, Otchere J, Kumagai T, Anyan WK, Asahi H, Akao N, Wilson MD, Boakye DA, Ohta N: Administrative practices of wellness experts and use of artesunate-amodiaquine by community members for treating uncomplicated malaria in southern Ghana: implications for artemisinin-based combination therapy deployment. Trop Med Int Well being 2011, 16:1215?224. 42. United Nation General Assembly: Implementation of Basic Assembly Resolution 66/289 on Consolidating Gains and Accelerating Efforts to Control and Get rid of Malaria in Creating Nations, Especially in Africa, by 2015. 2012. United Nation document A/RES/66/289. 43. WHO: WHO Informal Consultation with Companies of Artemisinin-Based Pharmaceutical Merchandise in use for the Remedy of Malaria. Geneva: Planet Health Organization; 2007. 44. WHO: WHO briefing on Malaria Remedy Guidelines and artemisinin monotherapies. 2006. http://who.int/malaria/publications/atoz/ meeting_briefing19april.pdf. 45. Tucker M, Mutka T, Sparks K, Patel J, Kyle DE: Phenotype and genotype evaluation of in vitro-selected artemisinin-resistance progeny of plasmodium falciparum. Antimicrob Agent Chemother 2012, 56:302?14. 46. Witkowski B, Amaratunga C, Khim N, Sreng S, Chim P, Kim S, Lim P, Mao S, Sopha C, Sam B, Anderson JM, Duong S, Chuor CM, Taylor WR, Suon S, Mercereau-Puijalon O, Fairhurst RM, Menard D: Novel pheno typic assays for the detection of artemisinin-resistant Plasmodium falciparum malaria in Cambodia in vitro and ex-vivo drug-response research.2,4-Dibromo-3-methylpyridine supplier Lancet Infect Dis 2013, 13:1043?049.3-Bromo-4-methylpyridin-2-ol site 47.PMID:33568034 MOH: Suggestions for Case Management of Malaria in Ghana. Accra: Ministry of Wellness; 2009. 48. WHO: Survey of your top quality of chosen antimalarial medicines circulating in six nations of sub-Saharan Africa. 2011. http://who.int/ medicines/publications/WHO_QAMSA_report.pdf.49. Oduola AM, Milhous WK, Salako LA, Walker O, Desjardins RE: Lowered in-vitro susceptibility to mefloquine in West African isolates of Plasmodium falciparum. Lancet 1987, two:1304?305. 50. Simon F, Le BJ, Gaudebout C, Girard PM: Reduced sensitivity of Plasmodium falciparum to mefloquine in West Africa. Lancet 1988, 1:467?68. 51. Crockett M, Kain KC: Tafenoquine: a promising new antimalarial agent. Expert Opin Investig Drugs 2007, 16:705?15. 52. Pradines B, Mamfoumbi MM, Tall A, Sokhna C, Koeck JL, Fusai T, Mosnier J, Czarnecki E, Spiegel A, Trape JF, Kombila M, Rogier C: In vitro activity of tafenoquine against the asexual blood stages of Plasmodium falciparum isolates from Gabon, Senegal, and Djibouti. Antimicrob Agents Chemother 2006, 50:3225?226. 53. Divo AA, Geary TG, Jensen JB: Oxygen- and time-dependent effects of antibiotics and chosen mitochondrial inhibitors on Plasmodium falciparum in culture. Antimicrob Agents Chemother 1985, 27:21?7. 54. McColm AA, McHardy N: Evaluation of a array of antimicrobial agents against the parasitic protozoa, Plasmodium falciparum, Babesia rodhaini and Theileria parva in vitro. Ann Trop Med Parasitol 1984, 78:345?54. 55. Willerson D Jr, Rieckmann KH, Carson PE, Frischer H: Effects of minocycline against chloroquine-resistant falc.
